Comparative Pharmacology
Head-to-head clinical analysis: AIMOVIG versus UBROGEPANT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIMOVIG versus UBROGEPANT.
AIMOVIG vs UBROGEPANT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AIMOVIG (erenumab) is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function. CGRP is a neuropeptide involved in the pathophysiology of migraine; its release leads to vasodilation and activation of pain pathways.
Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. It binds to CGRP receptors, blocking the vasodilatory and pro-inflammatory effects of CGRP, thereby aborting migraine attacks without causing vasoconstriction.
70 mg subcutaneously once monthly; some patients may benefit from 140 mg subcutaneously once monthly.
50 mg or 100 mg orally once daily as needed for acute treatment of migraine attacks; maximum daily dose: 200 mg. Not for prophylactic use.
None Documented
None Documented
28 days (range 23-31 days) in healthy volunteers; supports monthly subcutaneous dosing.
Terminal elimination half-life is ~5-7 hours, supporting twice-daily dosing for migraine prevention.
Elimination via proteolytic catabolism; no renal or biliary excretion of intact antibody.
Primarily eliminated via biliary/fecal excretion (approximately 70% of dose recovered in feces) with ~30% renal excretion (mostly as unchanged drug).
Category C
Category C
CGRP Antagonist
CGRP Antagonist